ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Schmidt Confers With Califano, Fredrickson On NCI director; Senate Hearing March 15-16

February 18, 1977

Includes 8-page April 2002 Business & Regulatory Report.

May 3, 2002

Conversation With The Cancer Letter: Ronald DePinho Says Moon Shots Will Go On

January 18, 2013

Pazdur: Registration Trials Run By Groups Need Same Rigor As Industry Trials

March 25, 2011

In Brief: David Harrington Replaces Zelen At ECOG; Kushnet To Receive Ewing Layman’s Award

December 1, 1989

NIH Plans Consensus Conference On Ovarian Cancer April 5-7

January 28, 1994